COVID-19 and phosphodiesterase enzyme type 5 inhibitors
| Autor: | Ali I Al-Gareeb, Marwa S. Al-Niemi, Claire Lugnier, Hayder M Al-Kuraishy, Ali K Al-Buhadily, Nasser A. Al-Harchan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Sildenafil Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pulmonary disease Review Article 030204 cardiovascular system & hematology nucleotide phosphodiesterase enzyme Pathology and Forensic Medicine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Acute lung injury Medicine Instrumentation chemistry.chemical_classification Lung business.industry COVID-19 Phosphodiesterase Electronic Optical and Magnetic Materials 030104 developmental biology Enzyme medicine.anatomical_structure chemistry Nephrology Immunology business |
| Zdroj: | Journal of Microscopy and Ultrastructure |
| ISSN: | 2213-879X |
| DOI: | 10.4103/jmau.jmau_63_20 |
| Popis: | COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|